Category Archives: Diabetes

We are so proud of our young son who cares for us

Carers’ Appeal: ‘We’re so proud of him’

 

Young Carers, Lisa and Neil Calvert with Poppie-May Simpkins (5) and Callum Britton (9)

 

Published on Friday 5 August 2011 09:38

“I’M really proud of him. He does a really good job and I don’t know how I’d manage if he wasn’t helping me.”

 

Lisa Calvert, 38, from Wisbech Road, South Lynn, is cared for by her son, Callum Britton, aged nine. Mrs Calvert suffers with type-2 diabetes, ankylosing spondylitis – a form of inflammatory arthritis in the spine – and depression.

She was also diagnosed with conversion disorder in 2005, a condition in which people experience neurological symptoms such as numbness, blindness, paralysis or fits without a neurological cause.

How a Gene Linked to Both Alzheimer’s Disease and Type 2 Diabetes works

Researchers Identify How a Gene Linked to Both Alzheimer’s Disease and Type 2 Diabetes Works

Released: 7/18/2011 11:25 AM EDT
Source: Mount Sinai Medical Center

 

Newswise — Researchers at Mount Sinai School of Medicine have identified how a gene for a protein that can cause Type 2 diabetes, also possibly kills nerve cells in the brain, thereby contributing to Alzheimer’s disease.

The gene, called SorCS1, controls the generation of amyloid-beta (Abeta) in the brain. Abeta plays a key role in the development of Alzheimer’s disease. The researchers previously linked SorCS1 to Alzheimer’s disease and identified where the molecules lived in the cell, but not how they control Abeta. The new data were presented today at the Alzheimer’s Association’s Annual International Conference in Paris.

Nice rejects Lucentis for diabetes-related sight loss

Nice rejects Lucentis for diabetes-related sight loss

Thousands of people with diabetes will “needlessly lose their sight” due to a decision to withhold a drug on cost grounds, a charity has warned.

By , Medical Correspondent

6:30AM BST 15 Jul 2011 

Lucentis can cost as little as £1,500 per patient with diabetic macular oedema (DMO), or as much as £10,000, depending on the severity of the condition.

It had been shown to produce “rapid and sustained” improvements in vision among those treated, while currently approved laser treatments tend only to prevent further degeneration.